Chat with us, powered by LiveChat

Loading...

Plasma Fractionation Market Report

RA01945

Plasma Fractionation Market by Product (Immunoglobulin, Albumin, Coagulation Factors, Protease Inhibitors, and Others), Application (Neurology, Immunology, Hematology, Critical Care, Rheumatology, Pulmonology, and Others), End Users (Hospitals & Clinics, Clinical Research Laboratories, and Academic Institutes), and Regional Analysis (North America, Europe, Asia-Pacific, and LAMEA): Global Opportunity Analysis and Industry Forecast, 2019-2027

RA01945

Pages: 165

May 2021

COVID-19

pandemic has shown to have an enormous impact on most
industries.

Click Here to access our comprehensive analysis of the

Impact of covid-19 on Plasma Fractionation Market

Global Plasma Fractionation Market Analysis

The global plasma fractionation market is predicted to generate $45,803.2 million in the 2020-2027 timeframe, growing from $25,404.5 million in 2019 at a healthy CAGR of 7.0%.

Market Synopsis

Increasing cases of autoimmune diseases such as type 1 diabetes mellitus and rheumatoid arthritis, especially in old population, is expected to drive the market of plasma fractionation globally. 

However, emergence of various recombinant alternatives such as protease inhibitor and anti-thrombin, instead of plasma derived products, acts as a growth-restraining factor for the plasma fractionation market. 
According to the regional analysis of the market, the Asia-Pacific plasma fractionation market is anticipated to grow at a CAGR of 8.3% by generating a revenue of $13328.7 million during the review period.

Plasma Fractionation Overview

Plasma fractionation is a process of separating plasma components from blood donated by the donors. Plasma fractionation is the upcoming therapeutics which is used by the healthcare professionals to treatvarious autoimmune disorders. 

Impact Analysis of COVID-19 on the Global Plasma Fractionation Market

Though the novel coronavirus pandemic has had a devastating effect on several industries, the global plasma fractionation market has been found to experience significant growth during this period. As the COVID-19 pandemic entered its worse phase, more people were adversely affected from the viral infection with severe complications, which led to plasma trials for treatment. Plasma therapy emerged as a hope for the patients. Moreover, plasma fractionation therapy proved to be successful in treating a few COVID-19 patients. For instance, according to a news published in The Hindu on July 05, 2020 claimed that 16 COVID-19 patients recovered in Chennai’s Rajiv Gandhi Government General Hospital on the basis of the treatment.

Although, the pandemic brought some growth in the plasma fractionation market, it has also faced a reduction in the market shares. Supply of blood decreased due to deduction in number of donors for plasma extraction. However, this factor is equated with decrease in the demand for plasma derived products due to postponed surgical procedures owing to nationwide lockdown norms and decrease in hospital space for patients other than COVID-19 affected ones.  

Increasing Cases of Autoimmune Diseases to Surge the Market Growth

Rapid increase in the autoimmune disease cases among old age population is expected to accelerate the growth of the plasma fractionation market globally. Also, a surge in establishing plasma collection centers at various places is also expected to increase the revenue of plasma fractionation market. 

Apart from this, growing use of immunoglobulins in various neurological, hematological and other therapeutics is expected to further drive the plasma fractionation market. For instance, according to a news published in Businesswire, on September 09, 2020, a study report supported by Octapharma, IV immunoglobulin has improved hypoxia and decreased hospital stay for the COVID-19 patients. 

To know more about global plasma fractionation drivers, get in touch with our analysts here.

High Cost of Plasma Therapy to Restrain the Market Growth

Plasma therapy procedural is very expensive and is commonly opted by patients who can afford the treatment. This factor restrains the market from growth. Furthermore, growing use of recombinant alternatives like fibrinogen concentration and protease inhibitor for the treatment of autoimmune diseases has also obstructed the plasma fractionation market growth. Also, the restricted medical reimbursement policies further impede the growth of the market. 

Government Initiatives and Increasing Investments for Research and Development Activities to Fuel the Market

Increased government funding and company investments in research and development activities in plasma therapies are expected to raise the share of plasma fractionation market. The COVID-19 pandemic has given many opportunities to the biotech and biopharma companies to invest in the R&D activities related to plasma therapies. Many companies have initiated collaboration to find the effectiveness of plasma therapy on COVID-19 patients. For instance, Grifols, a biopharma company dedicated in manufacturing plasma derived products collaborated with Food and Drug Administration (FDA) and Biomedical Advanced Research Development Authority (BARDA) in March 2020 to develop plasma therapeutics for COVID-19. 

Furthermore, lifestyle such as consumption of alcohol and tobacco, fast food, and others are increasing the risk of inflammatory disorders in the people, which further increases the opportunities for the plasma fractionation market growth.  

To know more about global plasma fractionation market opportunities, get in touch with our analysts here. 

Global Plasma Fractionation Market, by Product

Based on product, the global plasma fractionation market is segmented into immunoglobulin, albumin, coagulation factors, protease inhibitors, and others. Immunoglobulin sub-segment is projected to generate the maximum revenue and show the fastest growth.

Global Plasma Fractionation Market, by Product

Source: Research Dive Analysis

The immunoglobulin sub-segment is predicted to have a dominating share in the global market and is expected to register a revenue of $ 22,439.3 million during the forecast period. It is also anticipated to have the fastest market growth and generated a revenue of $11862.3 million in 2019. The anticipated growth can be attributed to factors such as rising demand for immunoglobulin products due to rising cases of immunological and neurological diseases.

Global Plasma Fractionation Market, by Application

On the basis of application, the market has been sub-segmented into neurology, immunology, hematology, critical care, rheumatology, pulmonology, and others. Among the mentioned sub-segments, the hematology sub-segment is predicted to show the fastest growth, whereas the neurology sub-segment is projected to garner a dominant market share.

Global Plasma Fractionation Market, by Application

Source: Research Dive Analysis

The hematology sub-segment of the global plasma fractionation market is projected to have the fastest growth and surpass $5124.3 million by 2027, with an increase from $2462.2 million in 2019. This fast growth is due to the advances in the hematology sector such as introduction of various plasma derived therapies with skilled and experienced healthcare professionals.

The neurology sub-segment is anticipated to have a dominating share in the global market and register a revenue of $16862.3 million during the analysis timeframe. This sub-segment growth is attributed to the increasing use of plasma therapeutic proteins such as coagulation factors and more, for the treatment procedures of chronic diseases such as Alzheimer’s disease and others.

Global Plasma Fractionation Market, by End User

Based on end users, the analysis has been divided into hospitals & clinics, clinical research laboratories, and academic institutes. Out of these, the clinical research laboratory sub-segment is predicted to have the fastest growth and hospitals & clinics sub-segment is anticipated to garner the maximum revenue share in the global market.

Global Plasma Fractionation Market, by End User

Source: Research Dive Analysis

The clinical research laboratory sub-segment of the global plasma fractionation market is predicted to have a rapid growth and surpass $3564.9 million by 2027, with an increase from $1652.7 million in 2019 owing to the rising demand for plasma therapy for various chronic diseases. Also, increasing research and development activities for the plasma derived therapeutics are projected to boost the market in the coming years.

Hospitals & clinics sub-segment is predicted to have a dominating share in the global market and is expected to register a revenue of $41162.7 million during the analysis timeframe owing to improved healthcare facilities and infrastructure in hospitals, along with increasing use of plasma products in hospitals to treat various autoimmune diseases.

 Global Plasma Fractionation Market, Regional Insights:

The plasma fractionation market was investigated across North America, Europe, Asia-Pacific, and LAMEA.

Global Plasma Fractionation Market, Regional Insights

Source: Research Dive Analysis

The Market for Plasma Fractionation in North America to be the Most Dominant

The North America plasma fractionation market accounted $9933.2 million in 2019 and is projected to register a revenue of $16947.2 million by 2027. This growth is due to increased per capita healthcare expenditure in the U.S. and rising demand for better and advanced healthcare facilities among patients. Also, adoption of new and advanced technologies will further increase the market revenue of North America.

The Market for Plasma Fractionation in Asia-Pacific to be the Fastest Growing

The share of Asia-Pacific plasma fractionation market is anticipated to grow at a CAGR of 8.3% by registering a revenue of $13328.7 million by 2027. This is due to factors such as rising prevalence of hemophilia in countries like India and China and increasing old age population in the region. Also, constantly improving healthcare infrastructure and facilities will further add on to the market growth.

Competitive Scenario in the Global Plasma Fractionation Market

Product launches and mergers & partnership are common strategies followed by major market players.

Competitive Scenario in the Global Plasma Fractionation Market

Source: Research Dive Analysis

The key players operating in the global plasma fractionation market include Kedrion S.P.A, Sanquin, Octapharma, Japan Blood Products, Bio Products Laboratory, China Biologics Products Holdings, Biotest AG, CSL Behring, Octapharma AG, and Grifols.

Porter’s Five Forces Analysis for the Global Plasma Fractionation Market:

  • Bargaining Power of Suppliers: The suppliers in the plasma fractionation market are high in number. Several companies are working on product innovation and development and thus will charge more for their new products. Thus, there is less threat from the suppliers. 
    Thus, the bargaining power suppliers is moderate.
  • Bargaining Power of Buyers: Buyers are high in number and have huge bargaining power; they demand best services at low prices comparative to the other suppliers in the market. This increases the pressure on the plasma products manufacturing companies to offer the best service in a cost-effective way. Thus, buyers can freely choose the convenient service that best fits their preference. 
    Thus, the bargaining power of the buyers is high.
  • Threat of New Entrants: New companies entering the plasma fractionation market are adopting advanced technologies for innovations such as developing the best product in the minimum time frame. Also, these companies are implementing various effective strategies such as offering discounts and value propositions. However, new players have to face tough competition from the already established market players as they already have built a trust with their buyers.
    Thus, the threat of the new entrants is high.
  • Threat of Substitutes: Recombinant therapies is an alternative product for plasma therapy and are now widely used to cure autoimmune diseases.
    Thus, the threat of substitutes is moderate.
  • Competitive Rivalry in the Market: The competitive rivalry among industry leaders is rather intense, especially between the global players like Grifols and Biotest AG. These companies are launching their plasma derived products in the international market and strengthening the footprint worldwide. 
    Therefore, competitive rivalry in the market is high. 

Aspect

Particulars

  Historical Market Estimations

  2018-2019

  Base Year for Market Estimation

  2019

  Forecast Timeline for Market Projection

  2020-2027

  Geographical Scope

 North America, Europe, Asia-Pacific, LAMEA

  Segmentation by Product

  • Immunoglobulin
  • Albumin
  • Coagulation Factors
  • Protease Inhibitors
  • Others

  Segmentation by Application

  • Neurology
  • Immunology
  • Hematology
  • Critical Care
  • Rheumatology
  • Pulmonology
  • Others

  Segmentation by End-Users

  • Hospitals & Clinics
  • Clinical Research Laboratories
  • Academic Institutes

  Key Companies Profiled

  • Kedrion S.P.A
  • Sanquin
  • Octapharma
  • Japan Blood Products
  • Bio Products Laboratory
  • China Biologics Products Holdings
  • Biotest AG
  • CSL Behring
  • Octapharma AG
  • Grifols

Frequently Asked Questions
 

A. The global plasma fractionation market is predicted to generate $45,803.2 million in the 2020-2027 timeframe, growing from $25,404.5 million in 2019 at a healthy CAGR of 7.0%.

A. Octapharma AG, Grifols and Biotest AG are some of the prominent companies in the plasma fractionation market.

A. The Asia-Pacific region possesses great investment opportunities for investors to witness the most promising growth in the future.

A. The share of Asia-Pacific market is anticipated to grow at a CAGR of 8.3%.

A. Grifols and Octapharma AG are investing more on R&D activities for developing new products and technologies.

CHAPTER 1:RESEARCH METHODOLOGY

1.1.Desk research
1.2.Real time insights and validation
1.3.Forecast model
1.4.Assumptions and forecast parameters

1.4.1. Assumptions
1.4.2. Forecast parameters

CHAPTER 2:EXECUTIVE SUMMARY

2.1.360° summary
2.2.Product
2.3.Application
2.4.End-Users

CHAPTER 3:MARKET OVERVIEW

3.1.Market segmentation & definitions
3.2.Key takeaways

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.2.2.1 Top winning strategies, by year, 2020-2027*
3.2.2.2 Top winning strategies, by development, 2020-2027*(%)
3.2.2.3 Top winning strategies, by company, 2020-2027*

3.3.Porters five forces analysis
3.4.Market dynamics
3.5.Technology landscape
3.6.Regulatory landscape
3.7.Patent landscape
3.8.Market value chain analysis
3.9.Strategic overview
3.10.Impact of key regulations

CHAPTER 4:IMPACT OF COVID-19 ON PLASMA FRACTIONATION MARKET

4.1.Introduction

4.2.COVID-19 health assessment
4.3.Impact of COVID-19 on global     economy
4.4.Impact of COVID-19 on plasma fractionation market

4.4.1. Social impact
4.4.2. Technological impact
4.4.3. Investment scenario

4.5.Plasma Fractionation market size and forecast, by region, 2020-2027

CHAPTER 5:PLASMA FRACTIONATION MARKET BY PRODUCT

5.1.OVERVIEW

5.1.1. Market size and forecast, by product

5.2. IMMUNOGLOBULIN

5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region 
5.2.3. Market share analysis, by country

5.3. ALBUMIN

5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region 
5.3.3. Market share analysis, by country

5.4. COAGULATION FACTORS

5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region 
5.4.3. Market share analysis, by country

5.5. PROTEASE INHIBITORS

5.5.1. Key market trends, growth factors and opportunities
5.5.2. Market size and forecast, by region 
5.5.3. Market share analysis, by country

5.6. OTHERS

5.6.1. Key market trends, growth factors and opportunities
5.6.2. Market size and forecast, by region 
5.6.3. Market share analysis, by country

CHAPTER 6:PLASMA FRACTIONATION MARKET BY APPLICATION

 6.1.OVERVIEW

 6.1.1. Market size and forecast, by application

 6.2. NEUROLOGY

 6.2.1. Key market trends, growth factors and opportunities
 6.2.2. Market size and forecast, by region 
 6.2.3. Market share analysis, by country

 6.3. IMMUNOLOGY

 6.3.1. Key market trends, growth factors and opportunities
 6.3.2. Market size and forecast, by region 
 6.3.3. Market share analysis, by country

 6.4. HEMATOLOGY

 6.4.1. Key market trends, growth factors and opportunities
 6.4.2. Market size and forecast, by region 
 6.4.3. Market share analysis, by country

 6.5. CRITICAL CARE

 6.5.1. Key market trends, growth factors and opportunities
 6.5.2. Market size and forecast, by region 
 6.5.3. Market share analysis, by country

 6.6. RHEUMATOLOGY

 6.6.1. Key market trends, growth factors and opportunities
 6.6.2. Market size and forecast, by region 
 6.6.3. Market share analysis, by country

 6.7. PULMONOLOGY

 6.7.1. Key market trends, growth factors and opportunities
 6.7.2. Market size and forecast, by region 
 6.7.3. Market share analysis, by country

 6.8. OTHERS

 6.8.1. Key market trends, growth factors and opportunities
 6.8.2. Market size and forecast, by region 
 6.8.3. Market share analysis, by country

CHAPTER 7:PLASMA FRACTIONATION MARKET BY END-USERS

7.1.OVERVIEW

7.1.1. Market size and forecast, by end-users

7.2. HOSPITALS AND CLINICS

7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by region 
7.2.3. Market share analysis, by country

7.3. CLINICAL RESEARCH LABORATORIES

7.3.1. Key market trends, growth factors and opportunities

7.3.2. Market size and forecast, by region 
7.3.3. Market share analysis, by country
7.4. ACADEMIC INSTITUTES

7.4.1. Key market trends, growth factors and opportunities

7.4.2.Market size and forecast, by region 
7.4.3.Market share analysis, by country

CHAPTER 8:  PLASMA FRACTIONATION MARKET BY REGION

 8.1. OVERVIEW

 8.1.1.Market size and forecast, by region

 8.2. NORTH AMERICA

 8.2.1.Key market trends and opportunities
 8.2.2.Market size and forecast, by product
 8.2.3.Market size and forecast, by application
 8.2.4.Market size and forecast, by end-users
 8.2.5.Market size and forecast, by Country

 8.2.6.U.S.

 8.2.6.1.Key market trends and opportunities
 8.2.6.2.Market size and forecast, by product
 8.2.6.3.Market size and forecast, by application
 8.2.6.4.Market size and forecast, by end-users

 8.2.7. Canada

 8.2.7.1.Key market trends and opportunities
 8.2.7.2.Market size and forecast, by product
 8.2.7.3.Market size and forecast, by application
 8.2.7.4.Market size and forecast, by end-users

 8.2.8. Mexico

 8.2.8.1.Key market trends and opportunities
 8.2.8.2.Market size and forecast, by product
 8.2.8.3.Market size and forecast, by application
 8.2.8.4.Market size and forecast, by end-users

 8.3. EUROPE

 8.3.1.Key market trends and opportunities
 8.3.2.Market size and forecast, by product
 8.3.3.Market size and forecast, by application
 8.3.4.Market size and forecast, by end-users
 8.3.5.Market size and forecast, by Country

 8.3.6.Germany

 8.3.6.1.Key market trends and opportunities
 8.3.6.2.Market size and forecast, by product
 8.3.6.3.Market size and forecast, by application
 8.3.6.4.Market size and forecast, by end-users

 8.3.7. UK

 8.3.7.1.Key market trends and opportunities

 8.3.7.2.Market size and forecast, by product
 8.3.7.3.Market size and forecast, by application
 8.3.7.4.Market size and forecast, by end-users

 8.3.8. France

 8.3.8.1.Key market trends and opportunities
 8.3.8.2.Market size and forecast, by product
 8.3.8.3.Market size and forecast, by application
 8.3.8.4.Market size and forecast, by end-users

 8.3.9. Spain

 8.3.9.1.Key market trends and opportunities
 8.3.9.2.Market size and forecast, by product
 8.3.9.3.Market size and forecast, by application
 8.3.9.4.Market size and forecast, by end-users

 8.3.10. Italy

 8.3.10.1.Key market trends and opportunities
 8.3.10.2.Market size and forecast, by product
 8.3.10.3.Market size and forecast, by application
 8.3.10.4.Market size and forecast, by end-users

 8.3.11. Rest of Europe

 8.3.11.1.Key market trends and opportunities
 8.3.11.2.Market size and forecast, by product
 8.3.11.3.Market size and forecast, by application
 8.3.11.4.Market size and forecast, by end-users

 8.4. ASIA-PACIFIC

 8.4.1.Key market trends and opportunities
 8.4.2.Market size and forecast, by product
 8.4.3.Market size and forecast, by application
 8.4.4.Market size and forecast, by end-users
 8.4.5.Market size and forecast, by Country

 8.4.6.China

 8.4.6.1.Key market trends and opportunities
 8.4.6.2.Market size and forecast, by product
 8.4.6.3.Market size and forecast, by application
 8.4.6.4.Market size and forecast, by end-users

 8.4.7. Japan

 8.4.7.1.Key market trends and opportunities
 8.4.7.2.Market size and forecast, by product
 8.4.7.3.Market size and forecast, by application
 8.4.7.4.Market size and forecast, by end-users

 8.4.8. India

 8.4.8.1.Key market trends and opportunities
 8.4.8.2.Market size and forecast, by product
 8.4.8.3.Market size and forecast, by application
 8.4.8.4.Market size and forecast, by end-users

 8.4.9. South Korea

 8.4.9.1.Key market trends and opportunities
 8.4.9.2.Market size and forecast, by product
 8.4.9.3.Market size and forecast, by application
 8.4.9.4.Market size and forecast, by end-users

 8.4.10. Australia

 8.4.10.1.Key market trends and opportunities
 8.4.10.2.Market size and forecast, by product
 8.4.10.3.Market size and forecast, by application
 8.4.10.4.Market size and forecast, by end-users

 8.4.11. Rest of Asia-Pacific

 8.4.11.1.Key market trends and opportunities
 8.4.11.2.Market size and forecast, by product
 8.4.11.3.Market size and forecast, by application
 8.4.11.4.Market size and forecast, by end-users

 8.5. LAMEA

 8.5.1.Key market trends and opportunities
 8.5.2.Market size and forecast, by product
 8.5.3.Market size and forecast, by application
 8.5.4.Market size and forecast, by end-users
 8.5.5.Market size and forecast, by Country

 8.5.6.Latin America

 8.5.6.1.Key market trends and opportunities
 8.5.6.2.Market size and forecast, by product
 8.5.6.3.Market size and forecast, by application
 8.5.6.4.Market size and forecast, by end-users

 8.5.7. Middle East

 8.5.7.1.Key market trends and opportunities
 8.5.7.2.Market size and forecast, by product
 8.5.7.3.Market size and forecast, by application
 8.5.7.4.Market size and forecast, by end-users

 8.5.8. Africa

 8.5.8.1.Key market trends and opportunities
 8.5.8.2.Market size and forecast, by product
 8.5.8.3.Market size and forecast, by application
 8.5.8.4.Market size and forecast, by end-users

 CHAPTER 9:  COMPANY PROFILES

 9.1.  KEDRION S.P.A

 9.1.1. Company overview
 9.1.2. Key executives
 9.1.3. Company snapshot
 9.1.4. Operating business segments
 9.1.5. Product portfolio
 9.1.6. R&D expenditure
 9.1.7. Business performance
 9.1.8. Key strategic moves and developments

 9.2.  SANQUIN

 9.2.1. Company overview
 9.2.2. Key executives
 9.2.3. Company snapshot
 9.2.4. Operating business segments
 9.2.5. Product portfolio
 9.2.6. R&D expenditure
 9.2.7. Business performance
 9.2.8. Key strategic moves and developments

 9.3.  OCTAPHARMA

 9.3.1. Company overview
 9.3.2. Key executives
 9.3.3. Company snapshot
 9.3.4. Operating business segments
 9.3.5. Product portfolio
 9.3.6. R&D expenditure
 9.3.7. Business performance
 9.3.8. Key strategic moves and developments

 9.4.  JAPAN BLOOD PRODUCTS

 9.4.1. Company overview
 9.4.2. Key executives
 9.4.3. Company snapshot
 9.4.4. Operating business segments
 9.4.5. Product portfolio
 9.4.6. R&D expenditure
 9.4.7. Business performance
 9.4.8. Key strategic moves and developments

 9.5.  BIO PRODUCTS LABORATORY

 9.5.1. Company overview
 9.5.2. Key executives
 9.5.3. Company snapshot
 9.5.4. Operating business segments
 9.5.5. Product portfolio
 9.5.6. R&D expenditure
 9.5.7. Business performance
 9.5.8. Key strategic moves and developments

 9.6.  CHINA BIOLOGICS PRODUCTS HOLDINGS

 9.6.1. Company overview
 9.6.2. Key executives
 9.6.3. Company snapshot
 9.6.4. Operating business segments
 9.6.5. Product portfolio
 9.6.6. R&D expenditure
 9.6.7. Business performance
 9.6.8. Key strategic moves and developments 

 9.7.  BIOTEST AG

 9.7.1. Company overview
 9.7.2. Key executives
 9.7.3. Company snapshot
 9.7.4. Operating business segments
 9.7.5. Product portfolio
 9.7.6. R&D expenditure
 9.7.7. Business performance
 9.7.8. Key strategic moves and developments

 9.8.  CSL BEHRING

 9.8.1. Company overview
 9.8.2. Key executives
 9.8.3. Company snapshot
9.8.4. Operating business segments
 9.8.5. Product portfolio
 9.8.6. R&D expenditure
 9.8.7. Business performance
 9.8.8. Key strategic moves and developments

 9.9.  OCTAPHARMA AG

 9.9.1. Company overview
 9.9.2. Key executives
 9.9.3. Company snapshot
 9.9.4. Operating business segments
 9.9.5. Product portfolio
 9.9.6. R&D expenditure
 9.9.7. Business performance
 9.9.8. Key strategic moves and developments

 9.10.  GRIFOLS

 9.10.1. Company overview
 9.10.2. Key executives
 9.10.3. Company snapshot
 9.10.4. Operating business segments
 9.10.5. Product portfolio
 9.10.6. R&D expenditure
 9.10.7. Business performance
 9.10.8. Key strategic moves and developments

Plasma fractionation is the technique of bifurcating plasma from the donated blood. Healthcare professionals use plasma fractionation to treat auto-immune disorders and therapeutics. Blood consists of approximately 55% plasma, 44% red blood cells, and 1% white blood cells. Plasma is the carrier of essential hormones, nutrients, and proteins throughout the body, apart from water, salt, and enzymes. The important components of plasma are clotting factors, antibiotics, fibrinogen, and protein albumin. These components are further separated and utilized for therapies for those suffering from shock, trauma, immune deficiency disease, burns, and rare chronic disorders. Plasma fractionation is carried out in two ways, namely – whole blood (recovered plasma) and apheresis (source plasma).

Forecast Analysis of Plasma Fractionation Market

The global plasma fractionation market is expected to enhance due to the swift rise in autoimmune diseases in the geriatric population. For instance, an article published on gulfnews.com stated that diabetes is considered as much deadlier than the Covid-19 virus as this disease kills three times more people every year than the novel coronavirus disease. Further, amongst the coronavirus deaths, almost 40% were reported to be diabetic. Also, this illness kills someone every eight seconds in the world, thus causing 4.2 million deaths in the year 2019, thrice the number than the Covid-19 deaths. According to the International Diabetes Society, by 2045, the diabetes numbers will rise to 629 million worldwide.

Apart from this, an upsurge in the plasma collections centers is predicted to drive the global market in the coming years. For instance, in July 2020, the Delhi Chief Minister, inaugurated the first plasma bank of India at the Institute of Liver & Biliary Sciences (ILBS) to simplify plasma access for the Covid-19 patients. The bank will coordinate will all the coronavirus recovered patients who are willing and eligible to donate plasma. Apart from this, the rise in the use of immunoglobulin in hematological, neurological, and therapeutics is projected to fuel the market in the upcoming years. Furthermore, as per a report offered by Research Dive, the global plasma fractionation market is anticipated to reach $45,803.2 million during the 2020-2027 forecasted period. Moreover, the North American market is estimated to rise rapidly due to a surge in the per capita expenditure on healthcare in the U.S.A and the availability of modern healthcare facilities. 

Recent Developments in the Market

The well-known participants of the global plasma fractionation market are concentrating on exclusive tactics such as mergers and acquisitions of prospering companies, constructing product portfolios, new product declarations, financing for the upcoming activities and innovations, and investments in research & development fields. These tactics are propelling the growth of several businesses worldwide. For instance, in April 2020, Octapharma, a pharmaceutical company, launched a project to explore therapies and has collaborated with global leaders in plasma fractionation to develop plasma-based hyper-immune immunoglobulin therapy for diagnosing Covid-19 disease. The leaders involved are CSL, BPL, Takeda, LFB, and Biotest. Furthermore, in August 2020, Alishech, Israel-based biotech & pharmaceutical company, built Russia’s biggest blood plasma fractionation plant. The plant consists of more than 25 drugs like albumin, immunoglobulin, and dried plasma to name a few.

Apart from this, in September 2019, Biopharma, a Ukrainian pharmaceutical company, introduced a plasma fractionator, the only biopharmaceutical company to do so in the eastern European region. The plasma obtained is used for preparing life-saving drugs and research & development projects. Also, in February 2019, Kedrion Biopharma, a pharmacy company, received approval from the FDA (Food & Drug Administration) for a plasma fractionation facility in Melville.

Covid-19 Impact on the Market

As the novel coronavirus disease affected more than half of the world’s population, plasma therapy seemed to be an emerging boon for all patients. Severe complications developed due to the Covid-19 disease are being treated with the plasma donated by the recovered coronavirus patients as these contain antibodies against the disease. For instance, in an article published on newindianexpress.com, B Venkatesh of Rayagada is one of the several people who is saving Covid-19 patients by donating and arranging plasma. Therefore, plasma fractionation processes are anticipated to be a huge success in obtaining plasma during the Covid-19 pandemic. 

Future Scope of the Market

An increase in the use of recombinant choices like protease inhibitor and fibrinogen concentration for diagnosis of autoimmune disorders is projected to hinder the market growth in the future years. However, the rise in company investments and government funding in research & development projects are estimated to open up promising opportunities in the market shortly. Apart from this, individual lifestyles such as alcohol consumption, fast food intake, and tobacco are increasing the chances of inflammatory disorders, thus leading to global market growth in the forthcoming years

Purchase Options

Personalize this research

  • Triangulate with your own data
  • Request your format and definition
  • Get a deeper dive on a specific application, geography, customer or competitor
10% Off on Customization
Contact Us

Customers Also Viewed